Coripharma develops generic oral solid pharmaceutical products. We offer other pharmaceutical companies the opportunity to in-license those products, along with a wide range of services such as assistance in mapping out the patent landscape, regulatory services, artwork design, manufacturing and packaging. This comprehensive service offering enables our customers to take their chosen products to their respective markets, at the date of patent expiry and under their own brand.
Robust performance history
Our R&D team is made up of almost 40 dedicated and highly qualified experts, who are involved at every stage of the development process. Between them, they have an exceptionally strong track record of successfully developing quality generic pharmaceutical products, a record based on more than two decades’ working with Coripharma’s predecessors Actavis, Medis and Teva.
We have a longstanding reputation for successful development projects and timely launches to European markets.
Coripharma’s R&D facility has advanced capability in the development of tablet, capsule and other oral solid dose formulations. It is located in Iceland, next to our manufacturing facility.
Our R&D team has a fully established process, ranging from identification/selection of products and formulations of interest to the timely completion of dossiers. We also manage responses to deficiency letters as part of regulatory processes, with complete independence in managing R&D workflow thanks to a full suite of in-house capabilities.